# Nephros to Participate in the Benchmark Company Annual Discovery One-on-One Investor Conference on December 11, 2024 in NYC
Canonical URL: https://biopharmsignal.com/news/NEPH/nephros-to-participate-in-the-benchmark-company-annual-discovery-one-on-one-inve-11af1579
Ticker: NEPH
Company: Nephros
Source: Nephros
Published: 2024-12-04 14:00 EST
## Summary

Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to...

## Article Body
Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will be participating in the Benchmark Company 13th Annual Discovery One-on-One Investor Conference. The event is scheduled for Wednesday, December 11, 2024, at the New York Athletic Club in New York City.

Robert Banks, CEO and Judy Krandel, CFO of Nephros, Inc. will be hosting one-on-one and group investor meetings. If you would like to schedule a 1x1 investor meeting please make sure you are registered here :

The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which Nephros will be participating in one-on-one meetings with investors and analysts throughout the day.

About The Benchmark Company

The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm’s sales, trading, and equity research capabilities. https://www.benchmarkcompany.com .

About Nephros Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within the healthcare and commercial markets, offering both proactive and emergency solutions for water management.

For more information about Nephros, please visit us at nephros.com .

Investor Relations Contacts: Kirin Smith, President PCG Advisory, Inc. (646) 823-8656 ksmith@pcgadvisory.com

Robert Banks, CEO Nephros, Inc. (201) 343-5202 x110 robert.banks@nephros.com
## Recent Company News
- 2026-07-20 11:00 EST — [Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET](https://biopharmsignal.com/news/NEPH/nephros-to-participate-in-the-health-wellness-longevity-virtual-conference-prese-04bc108f) — Source: Nephros
- 2026-07-06 11:00 EST — [Nephros Announces Inclusion in the Russell Microcap® Index](https://biopharmsignal.com/news/NEPH/nephros-announces-inclusion-in-the-russell-microcap-index-8f384e42) — Source: Nephros
- 2026-06-18 11:00 EST — [Nephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”](https://biopharmsignal.com/news/NEPH/nephros-to-host-virtual-investor-event-beyond-filtration-the-nephros-model-in-ac-6be1cdda) — Source: Nephros
- 2026-06-16 11:00 EST — [Nephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water](https://biopharmsignal.com/news/NEPH/nephros-positions-ultrafiltration-technology-as-a-solution-to-emerging-microplas-60dc48d7) — Source: Nephros
- 2026-05-07 20:05 EST — [Nephros Announces Financial Results for Quarter Ended March 31, 2026](https://biopharmsignal.com/news/NEPH/nephros-announces-financial-results-for-quarter-ended-march-31-2026-6679efc9) — Source: Nephros
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)